Pharmafile Logo
Pharmafocus logo
Advanced Search

Bertil Lindmark joins Almirall as R&D head

pharmafile | January 27, 2011 | Appointment | Research and Development |  Almirall, Bertil Lindmark, appointment, research and development 

Almirall has appointed Bertil Lindmark as executive director of R&D following the retirement of Dr Per-Olof Andersson.

Bertil joins the Spanish pharma company from AstraZeneca, where he served as VP and head clinical division at AstraZeneca Japan and before that as global therapy area clinical VP RITA (respiratory and inflammation therapy area).

He has 20 years’ experience in pharmaceutical R&D, with a focus on respiratory and extensive training in gastric diseases.

Advertisement

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025